Retatrutide and Tirzepatide
Records checked
Compiled and citation-checked by GLP-1 Receptor Agonists editorial desk
Qualified clinical review None on record
Retatrutide and Tirzepatide are curated as a pair under Incretin receptor agonists. This page reads them across four axes at once: what each one is recorded as binding, what the molecule is, what shape its indexed record set has, and what the application register returned. Every cell is either a sourced value or a count of records.
A larger record count is not a better compound. Counts track how long a compound has been studied and how heavily it has been indexed, nothing else. Nothing on this page ranks the two.
Identity and target
| Axis | Retatrutide | Tirzepatide |
|---|---|---|
| Class as recorded | Incretin receptor agonists | Incretin receptor agonists |
| Receptor targets as recorded | GIP receptor, GLP-1 receptor, Glucagon receptor | GIP receptor, GLP-1 receptor |
| Molecular formula | Unknown PubChem returned no compound record for this name on the retrieval date, so this field is not sourced. | C225H348N48O68[8] |
| Molecular weight | Unknown PubChem returned no compound record for this name on the retrieval date, so this field is not sourced. | 4813 g/mol[8] |
| CAS registry number | Unknown PubChem returned no compound record for this name on the retrieval date, so this field is not sourced. | 2023788-19-2[8] |
| Reported half-life | Unknown No pharmacokinetics source was retrieved in v1. PubChem does not carry half-life as a property, so this is recorded as not yet sourced rather than estimated. | Unknown No pharmacokinetics source was retrieved in v1. PubChem does not carry half-life as a property, so this is recorded as not yet sourced rather than estimated. |
| Applications on the register | None on the query date[4] | 2 on the query date[9] |
Shape of the indexed record set
| Axis | Retatrutide | Tirzepatide |
|---|---|---|
| Records indexed here | 12 | 12 |
| Phase 3 records | 1 | 7 |
| Phase 2 records | 2 | 1 |
| Phase 1 records | 0 | 0 |
| Trial records with no phase assigned | 1 | 3 |
| Review or synthesis records | 2 | 0 |
| Records that are not registered trials | 6 | 1 |
| Study models as assigned | other 5; rodent 4; human trial 3 | human trial 10; other 2 |
| Publication years covered | 2025–2026 | 2024–2025 |
| Derived record-set tier | Preparation or mixture | Human trial evidence |
| Basis of that tier | PubChem returned no compound record for this name, so the subject is a preparation, protein or mixture rather than a defined small molecule; identity fields are unsourced | 10 of 12 indexed records are interventional human trials by their own assigned publication type |
| Review state | Pending qualified review | Pending qualified review |
The derived tier counts record types. It is not an assessment of clinical efficacy, of safety, of study quality or of consensus, and the two tiers on this row are not a verdict about which compound is better supported.
Endpoint coverage, side by side
| Axis | Retatrutide | Tirzepatide |
|---|---|---|
| Body weight and adiposity | 7 | 9 |
| Glycaemic control | 6 | 3 |
| Cardiovascular | 2 | 6 |
| Renal | 2 | 0 |
| Hepatic | 1 | 1 |
| Neurological | 0 | 0 |
Each endpoint is defined by a fixed set of subject headings, printed in full on the endpoint pages.
Which axes diverge
17 of the 23 axes above differ between the two, 5 carry the same value, and 1 are unsourced on both sides. A divergence is a difference in what the corpus records, not a difference in what either compound does.
| Result | Axes |
|---|---|
| Differ | Receptor targets; Molecular formula; Molecular weight; CAS registry number; Applications on the register; Phase 3 records; Phase 2 records; Unphased trial records; Review records; Non-trial records; Study models; Publication years; Derived record-set tier; Body weight and adiposity records; Glycaemic control records; Cardiovascular records; Renal records |
| Same value | Class as recorded; Records indexed; Phase 1 records; Hepatic records; Neurological records |
| Unsourced on both sides | Reported half-life |
The corpus also carries a curated divergence note for this pair, written for the reference layer rather than for this one. It is not reproduced here; the records behind it are cited[1, 2, 3] and listed in the sources below.
Records indexed under both
No record in this corpus is indexed under both compounds. That is the absence of a retrieved head-to-head record in this selection, not evidence that none exists.
Where this page sits
- Retatrutide: the full indexed record set
- Tirzepatide: the full indexed record set
- Every curated pair in this class
Sources
- Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. Lancet (2023). pmid:37385280
- Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet (2021). pmid:34186022
- Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. N Engl J Med (2023). pmid:37366315
- Drugs@FDA application register query for this compound, no application records returned. U.S. Food and Drug Administration, openFDA drugsfda endpoint (2026). fda:retatrutide
- Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nat Med (2024). pmid:38858523
- Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial. Lancet Diabetes Endocrinol (2025). pmid:40609566
- A review of an investigational drug retatrutide, a novel triple agonist agent for the treatment of obesity. Eur J Clin Pharmacol (2024). pmid:38367045
- PubChem Compound Summary for CID 166567236, tirzepatide. PubChem, National Library of Medicine (2026). pubchem:166567236
- Drugs@FDA application register query for this compound, 2 application(s) returned: NDA215866, NDA217806. U.S. Food and Drug Administration, openFDA drugsfda endpoint (2026). fda:tirzepatide
- Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med (2021). pmid:34170647
- Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med (2022). pmid:35658024
- Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis. N Engl J Med (2024). pmid:38856224
- Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity. N Engl J Med (2025). pmid:39555826